Inebilizumab Sustains Efficacy & Safety During 5.5 Years
Investigators reported final safety and efficacy data from the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD), in which patients aged 18 and older who had an Expanded Disability Status Scale...
Read More